Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Oblimersen |
| Synonyms | |
| Therapy Description |
Genasense (oblimersen) is an antisense oligonucleotide that targets BCL-2, resulting in decreased protein expression, which potentially leads to increased tumor cell apoptosis (PMID: 24667300). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Oblimersen | Genasense|augmerosen|G3139 | BCL2 inhibitor 29 | Genasense (oblimersen) is an antisense oligonucleotide that targets BCL-2, resulting in decreased protein expression, which potentially leads to increased tumor cell apoptosis (PMID: 24667300). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|